Here are the DEF 14A proxy statements from Larimar Therapeutics, Inc. (LRMR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026, including a proposal to amend its charter to increase authorized common stock from 115,000,000 to 215,000,000 shares.
Stockholders will also vote on electing three Class III directors through 2029, advisory approvals of executive compensation and its voting frequency, ratifying PricewaterhouseCoopers as auditor for 2026, and a potential adjournment if there are insufficient votes for the share increase. The proxy highlights recent progress for nomlabofusp in Friedreich’s ataxia, including FDA Breakthrough Therapy Designation, alignment under the START pilot program toward a Biologics License Application using skin FXN as a surrogate endpoint, and positive long‑term open‑label data. It also notes two underwritten equity offerings in 2025–2026 raising roughly $65.0 million and $107.6 million in net proceeds, director and executive pay structures with a high proportion of at‑risk, performance‑based compensation, and a largely independent, six‑member staggered board with separate chair and CEO roles.